A complete guide to the precautions for using conceizumab

Concizumab (trade name: Alhemo), as an innovative drug, brings new hope to patients with hemophilia A and hemophilia B aged 12 years and above who have coagulation factor inhibitors. As the first prefilled hypodermic pen drug, its use has strict requirements. Patients and medical staff must follow relevant points to ensure drug safety and efficacy.

Cancelizumab is an anti-tissue factor pathway inhibitor (TFPI) antibody that effectively promotes coagulation and reduces the occurrence of bleeding events by blocking the interaction between TFPI and coagulation factor Xa (FXa). The design of its pre-filled injection pen greatly facilitates patients to self-administer medicine at home.

This medicine is mainly used to prevent or reduce the frequency of bleeding in patients with hemophilia A with FVIII inhibitors and hemophilia B with FIX inhibitors. However, use is strictly prohibited in patients with a history of severe allergy to cancelizumab or its components.

In terms of administration, subcutaneous injection is used, once a day, and the injection site can be alternately administered on the abdomen or thigh. The recommended dosing regimen is an initial loading dose of 1 mg/kg, followed by a daily maintenance dose of 0.2 mg/kg until an individualized maintenance dose is determined. 4 weeks after the start of treatment, the concizumab-mtci concentration in the plasma needs to be detected by ELISA to optimize the dose.

There are many precautions when using concezumab:

1.Allergic reaction: Injection site reaction, urticaria and other allergic symptoms may occur. Once severe allergy occurs, the medication must be stopped immediately and medical attention must be sought.

2. Thromboembolic events: High-dose or frequent breakthrough bleeding therapy will increase the risk of thromboembolic events. Patients should inform their doctor promptly if they notice signs and symptoms related to thromboembolism.

3.Drug interactions: Bypass drugs can be used to treat breakthrough bleeding, but high doses and frequent use will increase the risk of thromboembolism, so caution must be exercised.

4.Special groups: The safety of using this drug is unknown for pregnant women and they need to make careful decisions; lactating women, elderly patients and pediatric patients (especially children under 12 years old) have little experience in using this drug and need to evaluate it based on their specific conditions.

5.Storage of medicines: It needs to be stored in a refrigerator at 2°C to 8°C in the dark. It can be stored under the same conditions for 28 days after first use. Do not freeze or place near refrigerator cooling elements.

During medication, patients need to undergo regular blood tests, liver and kidney function tests, etc. to monitor whether the medication has adverse effects. Regular follow-up visits are critical to evaluate efficacy and adjust dosage.

In short, the safe and effective use of cancizumab relies on patients and medical staff to strictly follow the medication guidelines and precautions.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761315s000lbl.pdf